CYP2D6-Guided Opioid Management and Postoperative Pain Control
JAMA Network Open · 2026
DOI: 10.1001/jamanetworkopen.2025.58299 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA Network Open, 2026. Verfasst von Larisa H Cavallari und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville. Hauptthemen laut MEDLINE: Analgesics, Opioid, Cytochrome P-450 CYP2D6, Pain Management, Postoperative Pain. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHGRI NIH HHS.
Themen: Schmerzmanagement
Abstract (Originalsprache)
Importance Individuals with genetic variation that results in absent (poor metabolizers) or reduced (intermediate metabolizers) cytochrome P450 2D6 (CYP2D6) enzyme activity have lower concentrations of highly potent active metabolites of tramadol, hydrocodone, and codeine and are thus at increased risk for inadequate pain control.
Objective
To determine the effect of CYP2D6-guided opioid prescribing on postoperative pain and opioid use. Design, Setting, and Participants This open-label randomized clinical trial enrolled participants from surgery clinics at 8 US health systems. Individuals undergoing a planned surgery anticipated to cause postoperative pain for at least 7 to 10 days were enrolled from March 2021 to September 2023, with follow-up concluded in March 2024.
Intervention
Participants in the CYP2D6-guided arm underwent CYP2D6 genotyping before surgery, with recommendations to avoid tramadol, hydrocodone, and codeine for postoperative pain in CYP2D6 poor and intermediate metabolizers, as defined by genotype and use of CYP2D6 inhibitors. Participants in the control arm had usual pain management. Main Outcomes and Measures The primary outcome was the 10-day Silverman integrated analgesic assessment (SIA) score, a rank-based composite measure of average pain intensity on a 10-point scale, with higher scores indicating greater pain and opioid use (in morphine milligram equivalents [MMEs]). Secondary end points included individual components of the primary outcome and concordance between metabolizer phenotype and prescribed opioid 10 days after surgery. The primary analysis compared outcomes between poor and intermediate metabolizers in the CYP2D6-guided arm vs the control study arm. The analytical population comprised the subset of intent-to-treat participants with an actionable phenotype who completed surgery.
Results
Of 1602 participants enrolled, 351 (mean [SD] age, 62 [13] years; 237 [68%] female) had a CYP2D6 poor or intermediate metabolizer phenotype, proceeded to surgery, and were randomized to the CYP2D6-guided (n = 176) or control (n = 175) study arm. The most common procedures in the actionable population were total knee (177 [50%]) and total hip (97 [28%]) arthroplasties. Concordance between postsurgical opioid treatment and CYP2D6 phenotype was 64% (n = 112) in the CYP2D6-guided arm and 27% (n = 47) in the control arm (difference, 37 [95% CI, 27-46] percentage points; P < .001). At 10 days, the mean (SD) SIA score was 1.4 (95.9) in the CYP2D6-guided arm and −1.4 (93.1) in the control arm (difference, 2.8 [95% CI, −18.3 to 23.8]; P = .80). Mean (SD) numeric pain intensity rating (5.2 [2.2] and 5.1 [2.3]), overall opioid use (13.7 [14.9] and 13.2 [14.7] MME/d), and other secondary end points did not differ between the CYP2D6-guided arm and the control arm. Conclusions and Relevance In this randomized clinical trial of CYP2D6-guided postoperative opioid prescribing, there were significant prescribing changes in CYP2D6 poor and intermediate metabolizers but no differences in pain control compared with usual care. The data do not support a role for CYP2D6-guided opioid therapy in the contemporary postoperative setting of multimodal pain management. Trial Registration ClinicalTrials.gov Identifier: NCT05966129
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville.
- Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville.
- Clinical Research Unit, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
- Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina.
- Department of Medicine, Indiana University School of Medicine, Indianapolis.
- Florida Orthopaedic Institute, Gainesville.
Förderung
- NHGRI NIH HHS
Zitieren
APA
Cavallari, L. H., Myers, R. A., Chakraborty, H., Skaar, T. C., Gray, C. F., Baye, J. F., Volpi, S., Rider, R., Cicali, E. J., Elwood, E. N., Harris, E. C., Hines, L. J., Nahid, N. A., Nguyen, K. A., Obeng, A. O., Parr, J. A., Ramos, M. A., Orlando, L. A., Prieto, H. A., …, & IGNITE Pragmatic Trials Network (2026). CYP2D6-Guided Opioid Management and Postoperative Pain Control. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.58299
Vancouver
Cavallari LH, Myers RA, Chakraborty H, Skaar TC, Gray CF, Baye JF, et al. CYP2D6-Guided Opioid Management and Postoperative Pain Control. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2025.58299
BibTeX
@article{Cavallari2026,
author = {Cavallari, Larisa H and Myers, Rachel A and Chakraborty, Hrishikesh and Skaar, Todd C and Gray, Chancellor F and Baye, Jordan F and Volpi, Simona and Rider, Renee and Cicali, Emily J and Elwood, Erica N and Harris, Elizabeth C and Hines, Lindsay J and Nahid, Noor A and Nguyen, Khoa A and Obeng, Aniwaa Owusu and Parr, J Andrew and Ramos, Michelle A and Orlando, Lori A and Prieto, Hernan A and Sadeghpour, Azita and Singh, Rajbir and Starostik, Petr and Tillman, Emma M and Wyatt, Christina and Horowitz, Carol R and Voora, Deepak and Blake, Kathryn V and Parvataneni, Hari K and Fillingim, Roger B and Dexter, Paul R and Peterson, Josh F and Johnson, Julie A and IGNITE Pragmatic Trials Network, IGNITE Pragmatic Trials Network},
title = {CYP2D6-Guided Opioid Management and Postoperative Pain Control},
journal = {JAMA Network Open},
year = {2026},
doi = {10.1001/jamanetworkopen.2025.58299}
}
EUVIMED